News

February 12, 2020

EnGeneIC Novel Oncology-Focused Nanotechnology Featured in InsightsCare The 10 Most Innovative Healthcare Nanotech Companies to Watch

December 18, 2019

Winner in Drug Delivery Technology category by Fierce Innovation Awards – Life Sciences Edition 2019

EnGeneIC Wins Australian Financial Review Innovation Awards as most Innovative company in healthcare in Australia and New Zealand

EnGeneIC Announces First Patients with Advanced-Stage Pancreatic Cancer Dosed in Phase 1-2a Clinical Study

EnGeneIC Announces Publication of Preclinical Data Highlighting Potential Efficacy of EGFR-Targeted EDV(TM) Nanocells to Treat Pediatric Neuroblastoma

September 5, 2017

EnGeneIC Announces Publication in The Lancet Oncology of First Clinical Study Employing EDV™ Nanocell Platform to Enable microRNA Replacement Therapy

EnGeneIC Doses First Patient in U.S. Phase 1 Clinical Study of Targeted EDV™ Nanocells in Recurrent Glioblastoma Multiforme

EnGeneIC Receives FDA Orphan Drug Designation for Targeted EDV™ Nanocells to Treat Glioblastoma Multiforme

Cancer breakthrough: Sydney scientists record ‘near complete elimination’ in male mesothelioma patient, similar results in dogs

October 9, 2016

EnGeneIC Enters Into Research Collaboration with Takeda to Develop EDV™-Based Immunomodulatory Therapies for Oncology

October 3, 2016

EnGeneIC’s Joint-CEO and Co-Founder, Jennifer MacDiarmid, Ph.D., Recognized in Innovation Category in The Australian Financial Review and Westpac 100 Women of Influence Awards for 2016

EnGeneIC Announces Publication of Late-Stage Canine Brain Cancer Study Results in PLOS ONE

EnGeneIC Ltd. to Present at BIO CEO & Investor Conference 2016.

EnGeneIC receives Science Meets Business Top 25 Australian R&D spin-off companies award.

January 25, 2016

EnGeneIC Ltd. Strengthens Board of Directors to Support U.S. Expansion

January 5, 2016

EnGeneIC Limited to Present at the 34th Annual J.P. Morgan Healthcare Conference